Table 3 Odds ratios and 95% confidence intervals for incidence of TLS using logistic regression models

Age ≥ 65 years

0.83 (0.30–2.28)

0.720

–

–

–

–

Male sex

2.75 (0.93–8.10)

0.067

–

–

2.29 (0.74–7.12)

0.153

BMI > 22.4 (median value on study population)

0.73 (0.26–2.06)

0.559

0.58 (0.20–1.67)

0.310

–

–

Bortezomib-containing therapy

3.10 (0.86–11.10)

0.083

3.11 (0.86–11.30)

0.084

3.40 (0.91–12.70)

0.069

Route for bortezomib administration (Intravenously)

1.82 (0.38–8.64)

0.451

1.92 (0.39–9.37)

0.422

–

–

ISS stage III

2.69 (0.98–7.38)

0.055

2.48 (0.88–6.94)

0.085

1.67 (0.50–5.59)

0.409

β2 microglobulin > ULN

0.79 (0.09–6.76)

0.831

0.60 (0.06–5.75)

0.661

–

–

Serum albumin > ULN

1.57 (0.42–5.90)

0.501

1.32 (0.33–5.33)

0.698

–

–

Lactic dehydrogenase level > ULN

0.93 (0.29–2.99)

0.902

0.91 (0.28–2.96)

0.877

–

–

Pretreatment SCr level > ULN

3.32 (1.14–9.09)

0.027

3.20 (1.12–9.19)

0.030

2.09 (0.61–7.16)

0.241

Pretreatment serum uric acid level > ULN

2.56 (0.92–7.14)

0.072

2.11 (0.73–6.08)

0.166

1.71 (0.56–5.20)

0.344

Serum calcium > ULN (presence of hypercalcemia)

1.47 (0.31–6.99)

0.631

1.19 (0.24–5.81)

0.833

–

–

Plasma cells in bone marrow (%)

1.00 (0.97–1.03)

0.956

1.00 (0.97–1.03)

0.990

–

–

Presence of plasma cell in peripheral blood

0.99 (0.21–4.59)

0.985

0.94 (0.20–1.45)

0.936

–

–

Serum free light chain ratio > 1000

1.14 (0.14–9.51)

0.901

0.96 (0.11–8.40)

0.969

–

–

Hydration ^a

1.23 (0.46–3.32)

0.684

1.20 (0.42–3.45)

0.729

–

–

Urine alkalization

1.14 (0.31–4.28)

0.843

1.07 (0.28–4.16)

0.919

–

–